EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.36
−0.31%Year over year
Reported trailing growth
- Revenue
- -9.6%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -44.6%
- Operating cash flow
- -42.2%
Forward estimates
Based on analyst estimates
- Revenue
- -4.8%
- EBITDA
- —
- EPS
- +113.4%
Three-year CAGR
- Revenue
- -12.7%
- EBITDA
- +91.3%
- EBIT
- +201.4%
- Net income
- +127.6%
- EPS
- +127.2%
- Free cash flow
- +338.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026